These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2410673)

  • 1. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
    Kerr MJ; Allen JD; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog.
    Latini R; Gillis AM; Kates RE
    J Cardiovasc Pharmacol; 1984; 6(4):663-7. PubMed ID: 6206322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide.
    Gomoll AW; Byrne JE; Antonaccio MJ
    Am J Cardiol; 1986 Aug; 58(5):10C-17C. PubMed ID: 3092614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
    Davy JM; Dorian P; Kantelip JP; Harrison DC; Kates RE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):907-11. PubMed ID: 3086540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog.
    Dawson AK; Roden DM; Duff HJ; Woosley RL; Smith RF
    Am J Cardiol; 1984 Sep; 54(6):654-8. PubMed ID: 6475789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia.
    Roden DM; Dawson AK; Duff HJ; Woosley RL; Smith RF
    J Cardiovasc Pharmacol; 1984; 6(4):588-95. PubMed ID: 6206311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
    Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL
    J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiarrhythmic action of encainide versus ventricular arrhythmias in the conscious dog following coronary artery ligation.
    Byrne JE; Gomoll AW
    Can J Physiol Pharmacol; 1982 Mar; 60(3):369-75. PubMed ID: 6804074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encainide: a new antiarrhythmic agent.
    Wehmeyer AE; Thomas RL
    Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of encainide and its metabolites on energy requirements for defibrillation.
    Fain ES; Dorian P; Davy JM; Kates RE; Winkle RA
    Circulation; 1986 Jun; 73(6):1334-41. PubMed ID: 3084128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interaction studies and encainide use in renal and hepatic impairment.
    Quart BD; Gallo DG; Sami MH; Wood AJ
    Am J Cardiol; 1986 Aug; 58(5):104C-113C. PubMed ID: 2875643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic activity of the O-demethyl metabolite of encainide.
    Roden DM; Duff HJ; Altenbern D; Woosley RL
    J Pharmacol Exp Ther; 1982 Jun; 221(3):552-7. PubMed ID: 6806461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of antiarrhythmic response to encainide.
    Duff HJ; Roden DM; Carey EL; Wang T; Primm RK; Woosley RL
    Am J Cardiol; 1985 Nov; 56(13):887-91. PubMed ID: 3933319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.